Trends in prostate cancer mortality among black men and white men in the United States

Cancer

Volumn 97, Issue 6, 2003, Pages 1507-1516

  Chu, Kenneth C ^a   Tarone, Robert E ^a   Freeman, Harold P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Incidence; Mortality; Prostate cancer; Prostate specific antigen; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CAUCASIAN; CORRELATION ANALYSIS; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL; UNITED STATES;

EID: 0037443787     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11212     Document Type: Article

References (41)

1. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection [see comments]. J Natl Cancer Inst. 1990;82:1624-1628.
2. Brawley OW. Prostate cancer incidence and patient mortality: the effects of screening and early detection. Cancer. 1997;80:1857-1863.
3. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998;52:444-448.
4. Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev. 1994;3:105-111.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
6. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev. 1995;4:797-800.
7. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate cancer. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry [see comments]. Cancer. 1996;77:1342-1348.
8. Schwartz KL, Severson RK, Gurney JG, Montie JE. Trends in the stage specific incidence of prostate cancer in the Detroit metropolitan area, 1973-1994. Cancer. 1996;78: 1260-1266.
9. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997; 158:1427-1430.
10. Smart CR. The results of prostate cancer screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997;80:1835-1844.
11. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men [see comments]. Epidemiology. 1997;8:126-131.
12. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States [editorial]? [Published erratum appears in Cancer. 1998;82:1802.] Cancer. 1998;82: 249-251.
13. Hankey BF, Feuer E, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer - Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
14. Gann PH. Interpreting recent trends in prostate cancer incidence and mortality [editorial]. Epidemiology. 1997;8:117-120.
15. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - Part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025-1032.
16. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167-170.
17. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER*Stat version 4.2 [SEER cancer incidence public-use data base, 1973-1999]. Bethesda: National Cancer Institute, 2001.
18. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994;47:1451-1461.
19. Chu KC. Mortality rates by stage-at-diagnosis. Semin Surg Oncol. 1994;10:7-10.
20. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for Health Statistics, Division of Data Services, 2002. Available at: http://www.cdc.gov/nchs/.
21. Tarone RE, Chu KC. Evaluation of birth cohort patterns in population disease rates. Am J Epidemiol. 1996;143:85-91.
22. McCullagh P, Nelder JA. Generalized linear models. London: Chapman and Hall, 1989.
23. Chu KC. Re: "Temporal trends in diabetes mortality among American Indians and Hispanics in New Mexico: birth cohort and period effects" [letter]. Am J Epidemiol. 1998;147: 796-800.
24. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis cancer of the prostate treated with definitive radiotherapy: report of Radiation Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013-1021.
25. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer. Initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235-246.
26. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1999;337:295-300.
27. Roach M, Lu J, Pilepich MV, et al. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617-627.
28. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
29. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
30. Hanks GE, Lu J, Machtay M, et al. RTOG Protocol 92-02: a Phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys. 2000;48(Suppl 1):112.
31. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60-67.
32. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the "PSA era." Int J Cancer. 2001;92: 893-898.
33. Tarone RE, Chu KC, Gaudette LA. Birth cohort and calendar period trends in breast cancer mortality in the United States and Canada. J Natl Cancer Inst. 1997;89:251-256.
34. National Cancer Institute of Canada. Canadian cancer statistics 2001. Toronto: National Cancer Institute of Canada, 2001.
35. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000;355:1788-1789.
36. Oliver SE, Gunnell D, Donovan JL. Correction - comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000;356:1278.
37. Tannock IF. Eradication of a disease: how we cured symptomless prostate cancer. Lancet. 2002;359:1341-1342.
38. Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales, 1971-1998. BJU Int. 2000;85:1058-1062.
39. Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust. 1998;169:21-24.
40. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific-antigen mass screening in the federal state of Tyrol, Austria. Urology. 2001;58:417-424.
41. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8-22.